Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

BACKGROUND: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I mutation in Bcr/Abl, which confers resistance to the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Fei, Fei, Lim, Min, Schmidhuber, Sabine, Moll, Jürgen, Groffen, John, Heisterkamp, Nora
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2012
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489684/
https://ncbi.nlm.nih.gov/pubmed/22721004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-42
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller